GlassScriptPhysician profile
Ekene A Ezenwa
NPI 1689293672
$5,651.14
in general payments reported to CMS, 2019-2025
15 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $1,198 · 2023: $679 · 2024: $932 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Consulting Fee: $1,900 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.10 |
| Consulting Fee | $1,900.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma As | $1,900.00 | 2025 | |
| Abbvie INC. | $1,080.73 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $425.35 | 2024-2025 | Tremfya |
| Genzyme Corporation | $361.78 | 2021-2024 | |
| Ucb, INC. | $320.75 | 2021-2023 | Cimzia |
| Regeneron Healthcare Solutions, INC. | $305.17 | 2022-2023 | Libtayo |
| Janssen Biotech, INC. | $229.01 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $220.59 | 2021-2022 | |
| Lilly USA, LLC | $220.31 | 2022-2025 | Ebglyss |
| Incyte Corporation | $166.24 | 2022-2024 | |
| Vyne Pharmaceuticals INC. | $118.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 | |
| Pfizer INC. | $84.84 | 2022 | |
| Organon LLC | $67.35 | 2025 | Nexplanon |
| Dermavant Sciences, INC. | $52.55 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekene Ezenwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.